[1] Deenen J C, Horlings C G, Verschuuren J J, et al. The epidemiology of neuromuscular disorders: a comprehensive overview of the literature[J]. J Neuromuscul Dis, 2015, 2(1): 73-85.
[2] Beckers P J, Mercelis R, Heyman S, et al. Myasthenia gravis appearing after thymectomy heralding recurrent thymoma[J]. Acta Chir Belg, 2019, 119(3): 195-197.
[3] Kasparbauer A M, Petrovsky N, Schmidt P M, et al. Effects of nicotine and atomoxetine on brain function during response inhibition[J]. Eur Neuropsychopharmacol, 2019, 29(2): 235-246.
[4] 井 峰, 陈 兵. 人型结核分枝杆菌H37Ra在构建实验性自身免疫性重症肌无力大鼠模型中的应用[J]. 武警医学, 2019, 30(5): 391-394.
[5] Hong Y, Zisimopoulou P, Trakas N, et al. Multiple antibody detection in 'seronegative' myasthenia gravis patients[J]. Eur J Neurol, 2017, 24(6): 844-850.
[6] Ghazanfari N, Trajanovska S, Morsch M, et al. The mouse passive-transfer model of MuSK myasthenia gravis: disrupted MuSK signaling causes synapse failure[J]. Ann N Y Acad Sci, 2018, 1412(1): 54-61.
[7] Leite M I, Jacob S, Viegas S, et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis[J]. Brain, 2008, 131(7): 1940-1952.
[8] Stankovic M, Peric S, Stojiljkovic Tamas O, et al. Quality of life in patients with MuSK positive myasthenia gravis[J]. Acta Neurol Belg, 2018, 118(3): 423-427.
[9] 接明明, 黄晓军, 万彦婷, 等. 重症肌无力的中医药治疗研究进展[J]. 武警医学, 2017, 28(4): 407-409.
[10] Rivner M H, Pasnoor M, Dimachkie M M, et al. Muscle-specific tyrosine kinase and myasthenia gravis owing to other antibodies[J]. Neurol Clin, 2018, 36(2): 293-310.
[11] Ben Younes T, Benrhouma H, Klaa H, et al. Muscle-specific kinase autoimmune myasthenia gravis: report of a pediatric case and literature review[J]. Neuropediatrics, 2019, 50(2): 116-121.
[12] Koneczny I, Rennspiess D, Marcuse F, et al. Characterization of the thymus in lrp4 myasthenia gravis: four cases[J]. Autoimmun Rev, 2019, 18(1): 50-55.
[13] Bacchi S, Kramer P, Chalk C. Autoantibodies to low-density lipoprotein receptor related protein 4 in double seronegative myasthenia gravis: a systematic review[J]. Can J Neurol Sci, 2018, 45(1): 62-67.
[14] Stergiou C, Lazaridis K, Zouvelou V, et al. Titin antibodies in "seronegative" myasthenia gravis-a new role for an old antigen[J]. J Neuroimmunol, 2016, 29(2): 108-115.
[15] Kruger J M, Karussis D, Zisimopoulou P, et al. Low density lipoprotein receptor related protein 4-positive myasthenia gravis in a double seronegative, electromyography negative patient[J]. J Neuroophthalmol, 2017, 37(3): 285-286.
[16] Zhao G, Wang X, Yu X, et al. Clinical application of clustered-ACHR for the detection of SNMG[J]. Sci Rep, 2015, 5(1): 190-193.
[17] Hong Y, Li H F, Skeie G O, et al. Autoantibody profile and clinical characteristics in a cohort of Chinese adult myasthenia gravis patients[J]. J Neuroimmunol, 2016, 29(8): 51-57.
[18] Kufukihara K, Watanabe Y, Inagaki T, et al. Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and/or myocarditis[J]. Sci Rep, 2019, 9(1): 52-84.
[19] Nagappa M, Mahadevan A, Gangadhar Y, et al. Autoantibodies in acquired myasthenia gravis: clinical phenotype and immunological correlation[J]. Acta Neurol Scand, 2019, 139(5): 428-437.
[20] Ohno K, Ito M, Kawakami Y, et al. Collagen is a key player for developing rational therapy for congenital myasthenia and for dissecting the mechanisms of anti-muSK myasthenia gravis[J]. J Mol Neurosci, 2014, 53(3): 359-361.
[21] Zoltowska Katarzyna M, Belaya K, Leite M, et al. Collagen Q--a potential target for autoantibodies in myasthenia gravis[J]. J Neurol Sci, 2015, 348(1-2): 241-244.
[22] Cortes V E, Gallardo E, Martinez M A, et al. Clinical characteristics of patients with double seronegative myasthenia gravis and antibodies to cortactin[J]. JAMA Neurol, 2016, 73(9): 1099-1104.
[23] Gallardo E, Martinez H E, Titulaer M J, et al. Cortactin autoantibodies in myasthenia gravis[J]. Autoimmun Rev, 2014, 13(10): 1003-1007.
[24] Cordts I, Bodart N, Hartmann K, et al. Screening for lipoprotein receptor-related protein 4, agrin and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis[J]. J Neurol, 2017, 264(6): 1193-1203.
[25] Gilhus N E, Verschuuren J J. Myasthenia gravis: subgroup classification and therapeutic strategies[J]. Lancet Neurol, 2015, 14(10): 1023-1036.